Patient P-01603

Synthetic patientNBL-101 · Day 109 · 55–64 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Stable

Discontinuation risk

85%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 41 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 54 SC-12 recommended — Supportive Compound SC-12
Day 55 Patient accepted — Started SC-12 in the companion
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 61 GI symptom burden −12% vs expected — Supportive Compound SC-12
Day 67 Tolerance state changed — Unstable → Improving
Day 69 GI symptom burden −23% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 41.

Primary contributors, last 14 days

GI instability+16
Toxicity+10
Inflammatory activity+5
Treatment adherence-3

What helped?

Supportive Compound SC-12Day 54
Result: symptom burden −12%
GI Support Protocol GI-04Day 60
Result: symptom burden −23%

LIFE OS recommendation

Monitoring Escalation ME-01

85%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

51.6/100

improving · -1.7 vs previous 14 d

Toxicity

Blood

46.8/100

stable · +1.3 vs previous 14 d

Sleep quality

Wearable

35.7/100

improving · +4.1 vs previous 14 d

Energy level

Daily log

3.3/10

stable · -0.1 vs previous 14 d

Stress level

Daily log

6.8/10

stable · +0.1 vs previous 14 d

Steps

Wearable

8,321

improving · +760 vs previous 14 d

Adherence

Companion

50.4 %

stable · +1.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 30 from the failing basin, 58 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 77 similar · onset 3 d · confidence 73%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 73%

Would not help

Keep fat low
GI +7.4 next day on high-intake days · n 21
Keep histamine low
GI +6.4 next day on high-intake days · n 17
Keep simple carbs low
GI +3.5 next day on high-intake days · n 24

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+7.4detractor · 95%
Histamine load
+6.4detractor · 95%
Simple carbohydrates
+3.5detractor · 75%
Spicy / capsaicin
+2.5no signal · 49%
Alcohol
-1.1no signal · 15%
Insoluble fibre
+0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 52 and rising
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 49
Autonomic recovery ↓45
- WearableResting HR 82 bpm
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 33/100
Drug metabolism and exposure ↑20
- BloodToxicity index 47

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.2 · butyrate capacity 33/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 45 ms
Sleep: 6.4 h
Steps: 8,714
Resting HR: 81 bpm

Daily log: GI score 52, nutritional resilience 53, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01377	24%	S11	AD-05	no change	42
P-01483	23%	S14	AD-05	no change	35
P-01689	24%	S13	BR-03	no change	50
P-01350	23%	S19	BR-03	no change	34
P-01708	31%	S07	CR-01	improved	59
P-01371	30%	S06	CR-01	improved	63
P-01696	29%	S20	CR-01	improved	59
P-01388	28%	S17	CR-01	improved	59
P-01442	28%	S13	CR-01	improved	61
P-01835	28%	S17	CR-01	improved	56
P-01877	25%	S01	CR-01	improved	67
P-01430	24%	S05	CR-01	improved	54